1,005 reports of this reaction
3.2% of all PANITUMUMAB reports
#3 most reported adverse reaction
DERMATITIS ACNEIFORM is the #3 most commonly reported adverse reaction for PANITUMUMAB, manufactured by Amgen, Inc. There are 1,005 FDA adverse event reports linking PANITUMUMAB to DERMATITIS ACNEIFORM. This represents approximately 3.2% of all 31,648 adverse event reports for this drug.
Patients taking PANITUMUMAB who experience dermatitis acneiform should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DERMATITIS ACNEIFORM is moderately reported among PANITUMUMAB users, representing a notable but not dominant share of adverse events.
In addition to dermatitis acneiform, the following adverse reactions have been reported for PANITUMUMAB:
The following drugs have also been linked to dermatitis acneiform in FDA adverse event reports:
DERMATITIS ACNEIFORM has been reported as an adverse event in 1,005 FDA reports for PANITUMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
DERMATITIS ACNEIFORM accounts for approximately 3.2% of all adverse event reports for PANITUMUMAB, making it one of the most commonly reported side effect.
If you experience dermatitis acneiform while taking PANITUMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.